Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
1q gain/amplification
daratumumab
relapsed refractory MM
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
12
06
2019
accepted:
13
09
2019
pubmed:
11
12
2019
medline:
24
11
2020
entrez:
11
12
2019
Statut:
ppublish
Résumé
Gain of chromosome 1q21 and the gene expression-based GEP70 risk score are established prognostic markers for newly diagnosed Multiple Myeloma (MM) patients. Here we addressed the prognostic impact of these two markers in 81 relapsed/refractory (RR) MM patients treated with the CD38-antibody daratumumab. Fluorescence in situ hybridization for 1q21 was performed at initial presentation, while the GEP70 score was determined at initial presentation and prior to daratumumab treatment. While the GEP70 at initial presentation showed a trend for inferior survival, the GEP70 collected prior to daratumumab treatment was significantly associated with poor outcome (P < 0·05). The worst outcome was seen for patients who were positive for gain(1q) and classified as GEP70 high risk prior to daratumumab [progression-free (PFS) and overall survival (OS) of 0·3 years (95% CI: 0·15-1·4 years) and 0·8 years (95% CI: 0·5-1·9 years) respectively], while the median PFS and OS were not reached by patients without gain(1q) and GEP70 low-risk status. In conclusion, gain(1q) and the GEP70 are powerful prognostic markers for RR MM patients treated with daratumumab, and patients classified as high risk according to these markers experience shorter treatment response.
Substances chimiques
Antibodies, Monoclonal
0
daratumumab
4Z63YK6E0E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-71Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Références
An, G., Xu, Y., Shi, L., Shizhen, Z., Deng, S., Xie, Z., Sui, W., Zhan, F. & Qiu, L. (2014) Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica, 99, 353-359.
Chari, A., Martinez-Lopez, J., Mateos, M.V., Bladé, J., Benboubker, L., Oriol, A., Arnulf, B., Rodriguez-Otero, P., Pineiro, L., Jakubowiak, A. & de Boer, C. (2019) Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood, 134, 421-431.
Dimopoulos, M.A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N.J., Usmani, S.Z., Rabin, N., Orlowski, R.Z., Komarnicki, M., Suzuki, K. & Plesner, T. (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine, 375, 1319-1331.
Facon, T., Kumar, S., Plesner, T., Orlowski, R.Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H. & Goldschmidt, H. (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. New England Journal of Medicine, 380, 2104-2115.
Hanamura, I., Stewart, J.P., Huang, Y., Zhan, F., Santra, M., Sawyer, J.R., Hollmig, K., Zangarri, M., Pineda-Roman, M., Van Rhee, F. & Cavallo, F. (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood, 108, 1724-1732.
Hussain, M.J., Robinson, M.M., Hamadeh, I., Arnall, J., Bhutani, M., Atrash, S., Friend, R., Pineda-Roman, M., Symanowski, J.T., Usmani, S.Z. & Voorhees, P.M. (2018) Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma. British Journal of Haematology, 186, 140-144.
Lokhorst, H.M., Plesner, T., Laubach, J.P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M.C., Lassen, U., Krejcik, J., Palumbo, A. & van de Donk, N.W. (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. New England Journal of Medicine, 373, 1207-1219.
Lonial, S., Weiss, B.M., Usmani, S.Z., Singhal, S., Chari, A., Bahlis, N.J., Belch, A., Krishnan, A., Vescio, R.A., Mateos, M.V. & Mazumder, A. (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet, 387, 1551-1560.
Mateos, M.V., Dimopoulos, M.A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P. & Pour, L. (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. New England Journal of Medicine, 378, 518-528.
Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M.C., Broijl, A., Caillon, H., Caillot, D. & Corre, J. (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet, 394, 29-38.
Nair, B., Shaughnessy, J.D., Zhou, Y., Astrid-Cartron, M., Qu, P., van Rhee, F., Anaissie, E., Alsayed, Y., Waheed, S., Hollmig, K. & Szymonifka, J. (2009) Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood, 113, 6572-6575.
Nijhof, I.S., Casneuf, T., Van Velzen, J., van Kessel, B., Axel, A.E., Syed, K., Groen, R.W., van Duin, M., Sonneveld, P., Minnema, M.C. & Zweegman, S. (2016) CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood, 128, 959-970.
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A.K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M.V. & Mark, T.M. (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine, 375, 754-766.
Sawyer, J.R., Swanson, C.M., Koller, M.A., North, P.E. & William, Ross S. (1995) Centromeric instability of chromosome 1 resulting in multibranched chromosomes, telomeric fusions, and "jumping translocations" of 1q in a human immunodeficiency virus-related non-Hodgkin's lymphoma. Cancer, 76, 1238-1244.
Sawyer, J.R., Tian, E., Heuck, C.J., Epstein, J., Johann, D.J., Swanson, C.M., Lukacs, J.L., Johnson, M., Binz, R., Boast, A. & Sammartino, G. (2014) Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood, 123, 2504-2512.
Sawyer, J.R., Tian, E., Heuck, C.J., Johann, D.J., Epstein, J., Swanson, C.M., Lukacs, J.L., Binz, R.L., Johnson, M., Sammartino, G. & Zangari, M. (2015) Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood, 125, 3756-3759.
Sawyer, J.R., Tian, E., Walker, B.A., Wardell, C., Lukacs, J.L., Sammartino, G., Bailey, C., Schinke, C.D., Thanendrarajan, S., Davies, F.E. & Morgan, G.J. (2019) An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer Journal, 9, 62.
Usmani, S.Z., Jakubowiak, A., Chari, A., Lonial, S., Mateos, M.-V., Benboubker, L., Wu, K., Khokhar, N.Z., Wang, J., Doshi, P. & Moreau, P. (2017) 997PDSplit dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM). Annals of Oncology, 28(Suppl 5).
Usmani, S.Z., Nahi, H., Mateos, M.V., van de Donk, N.W., Chari, A., Kaufman, J.L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., Hellemans, P., Masterson, T., Clemens, P.L., Luo, M., Liu, K. & San-Miguel, J. (2019) Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood, 134, 668-677.
Van Laar, R., Flinchum, R., Brown, N., Ramsey, J., Riccitelli, S., Heuck, C., Barlogie, B. & Shaughnessy, J.D. Jr. (2014) Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. BMC Medical Genomics, 7, 25.
Walker, B.A., Mavrommatis, K., Wardell, C.P., Ashby, T.C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A. & Samur, M. (2019) A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia, 33, 159-170.
Weinhold, N., Heuck, C.J., Rosenthal, A., Thanendrarajan, S., Stein, C.K., Van Rhee, F., Zangari, M., Hoering, A., Tian, E., Davies, F.E. & Barlogie, B. (2016) Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia, 30, 423-430.
Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B. & Anaissie, E. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020-2028.